ID

43982

Description

Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT02022761

Link

https://clinicaltrials.gov/show/NCT02022761

Keywords

Versions (2)
  1. 4/4/16 4/4/16 -
  2. 9/20/21 9/20/21 -
Uploaded on

September 20, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Asthma NCT02022761

English

Eligibility Asthma NCT02022761

1 forms  
  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT02022761
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. healthy male or female subjects 18 to 65 years of age, inclusive
Description

Age | Gender | Healthy Volunteers

Data type

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2,1]
C0079399
UMLS CUI [2,2]
C1708335
2. body mass index (bmi) within the range of 19.0 to 33.0 kg/m2, inclusive at screening
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855
3. minimum weight of 55.0 kg at screening and pre-dose day 1
Description

Body weight | Pre-dose | day

Data type

boolean

Alias
UMLS CUI [1]
C0005910
UMLS CUI [2,1]
C0439565
UMLS CUI [2,2]
C0439228
4. clinical diagnosis of asthma by a physician for ≥12 months prior to screening confirmed in writing and/or by medical records
Description

Asthma confirmed

Data type

boolean

Alias
UMLS CUI [1,1]
C0004096
UMLS CUI [1,2]
C3173473
5. mild asthmatics currently requiring treatment with low dose inhaled corticosteroids or other low intensity treatment or moderate asthmatics, requiring treatment with low dose inhaled corticosteroids and long-acting beta agonists, medium- high dose inhaled corticosteroids alone or low dose inhaled corticosteroids and other low intensity treatment8
Description

Mild asthma | Low-Dose Treatment | inhaled steroids | Moderate asthma | inhaled steroids | Adrenergic beta-2 Receptor Agonists

Data type

boolean

Alias
UMLS CUI [1]
C0581124
UMLS CUI [2,1]
C1708745
UMLS CUI [2,2]
C2065041
UMLS CUI [3,1]
C0581125
UMLS CUI [3,2]
C2065041
UMLS CUI [3,3]
C2936789
6. well controlled asthma for 1 month prior to dosing defined by the following:
Description

Persistent asthma, well controlled

Data type

boolean

Alias
UMLS CUI [1]
C3661869
1. daytime symptoms occur ≤8 times/ 4 weeks
Description

Asthma daytime symptoms

Data type

boolean

Alias
UMLS CUI [1]
C1276804
2. daily activity is not limited by asthma
Description

Asthma | daily activities | Limited

Data type

boolean

Alias
UMLS CUI [1]
C0004096
UMLS CUI [2,1]
C0871707
UMLS CUI [2,2]
C0439801
3. no nocturnal symptoms resulting in nighttime awakenings
Description

Asthma night-time symptoms | Nocturnal awakening

Data type

boolean

Alias
UMLS CUI [1]
C1273489
UMLS CUI [2]
C0860510
4. use of short-acting beta-agonist (saba) ≤8 times/4 weeks for the treatment of symptoms
Description

Adrenergic beta-2 Receptor Agonists | treat symptoms

Data type

boolean

Alias
UMLS CUI [1,1]
C2936789
UMLS CUI [1,2]
C2146147
7. there has been no change in asthma medication (dose or regimen) within 4 weeks prior to dosing
Description

Asthma | Change of medication

Data type

boolean

Alias
UMLS CUI [1,1]
C0004096
UMLS CUI [1,2]
C0580105
8. pre-short-acting β2 agonist (saba) forced expiratory volume in 1 second (fev1) of
Description

Adrenergic beta-2 Receptor Agonists | FEV1

Data type

boolean

Alias
UMLS CUI [1]
C2936789
UMLS CUI [2]
C0748133
≥80 percent of predicted normal values at screening
Description

FEV1

Data type

boolean

Alias
UMLS CUI [1]
C0748133
9. non-smokers for at least 6 months prior to screening and agrees not to smoke during the study
Description

Non-smoker

Data type

boolean

Alias
UMLS CUI [1]
C0337672
10. negative test results for smoking status at screening (urine cotinine) and pre-dose day 1 (smokerlyser)
Description

Smoking Status | Negative Test Result | Urine cotinine test negative

Data type

boolean

Alias
UMLS CUI [1,1]
C1519386
UMLS CUI [1,2]
C1334932
UMLS CUI [2]
C1696067
11. female subjects of childbearing potential must be practising true abstinence when this is in line with the preferred and usual lifestyle of the subject (periodic abstinence, e.g. calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception), or be using and willing to continue using a medically acceptable form of birth control for at least 1 month prior to screening (at least 3 months for hormonal contraceptives) and for at least 1 month after the last study drug administration
Description

Childbearing Potential | periodic abstinence | Rhythm method of contraception | Ovulation Inhibition | Temperature method of contraception | Withdrawal - birth control | Contraceptive methods | Hormonal contraception

Data type

boolean

Alias
UMLS CUI [1]
C3831118
UMLS CUI [2]
C1256761
UMLS CUI [3]
C0035513
UMLS CUI [4]
C0029968
UMLS CUI [5]
C0419534
UMLS CUI [6]
C3812880
UMLS CUI [7]
C0700589
UMLS CUI [8]
C2985296
12. male subjects of reproductive potential who are not truly abstinent must be using and willing to continue using medically acceptable contraceptive precautions from screening and for at least 1 month after the last study drug administration
Description

Male Contraception | Females & males of reproductive potential

Data type

boolean

Alias
UMLS CUI [1]
C0086580
UMLS CUI [2]
C4034483
13. female subjects must have a negative serum pregnancy test at screening and a negative urine pregnancy test pre-dose day 1
Description

Female | Serum pregnancy test negative | Urine pregnancy test negative

Data type

boolean

Alias
UMLS CUI [1,1]
C0086287
UMLS CUI [1,2]
C0430061
UMLS CUI [1,3]
C0430057
14. able to speak, read, and understand english sufficiently to understand the nature of the study, to provide informed consent, and to allow completion of all study assessments
Description

Able to speak | Able to read | Comprehension | English Language | Informed Consent | Compliance behavior

Data type

boolean

Alias
UMLS CUI [1,1]
C0564215
UMLS CUI [1,2]
C0586740
UMLS CUI [1,3]
C0162340
UMLS CUI [1,4]
C0376245
UMLS CUI [2]
C0021430
UMLS CUI [3]
C1321605
15. must provide written informed consent prior to the initiation of any protocol-specific procedures
Description

Informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. a history of a life-threatening asthma exacerbation that required intubation and mechanical ventilation
Description

Exacerbation of asthma | Life Threatening | Intubation | Mechanical ventilation

Data type

boolean

Alias
UMLS CUI [1,1]
C0349790
UMLS CUI [1,2]
C2826244
UMLS CUI [2,1]
C0021925
UMLS CUI [2,2]
C0199470
2. history of severe asthma exacerbation in the last year that required the use of systemic corticosteroids (tablets, suspension or injection)
Description

Exacerbation of severe persistent asthma | systemic steroids

Data type

boolean

Alias
UMLS CUI [1]
C3508930
UMLS CUI [2]
C2825233
3. hospitalization or a visit to er because of asthma in the last year
Description

Hospitalization | previous emergency room visit | Asthma

Data type

boolean

Alias
UMLS CUI [1]
C0019993
UMLS CUI [2]
C2114437
UMLS CUI [3]
C0004096
4. intensive care admission for asthma in the previous 5 years
Description

Asthma | Admission to intensive care unit

Data type

boolean

Alias
UMLS CUI [1,1]
C0004096
UMLS CUI [1,2]
C0583239
5. any clinically significant abnormalities on clinical chemistry, haematology, or urinalysis, as judged by the investigator (at screening and/or day -1)
Description

Abnormality | Chemistry, Clinical | Hematology finding | Urinalysis

Data type

boolean

Alias
UMLS CUI [1,1]
C1704258
UMLS CUI [1,2]
C0008000
UMLS CUI [2]
C0474523
UMLS CUI [3]
C0042014
6. clinically significant abnormalities on physical examination, medical history, 12-lead ecg, or vital signs, as judged by the investigator (at screening or pre-dose day 1)
Description

Abnormality | Physical Examination | Medical History | 12 lead ECG | Vital signs

Data type

boolean

Alias
UMLS CUI [1,1]
C1704258
UMLS CUI [1,2]
C0031809
UMLS CUI [2]
C0262926
UMLS CUI [3]
C0430456
UMLS CUI [4]
C0518766
7. a qtcf >430 msec for male subjects and >450 msec for female subjects on ecg at screening or pre-dose day 1
Description

QTcF | Gender | Electrocardiogram

Data type

boolean

Alias
UMLS CUI [1]
C1882513
UMLS CUI [2]
C0079399
UMLS CUI [3]
C0013798
8. history or presence of any clinically significant illness (e.g., cardiovascular, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, musculoskeletal, or psychiatric) or any other condition, which in the opinion of the investigator would jeopardize the safety of the subject or the validity of the study results
Description

Illness (finding) | Cardiovascular Diseases | Liver diseases | Kidney Diseases | Hematological Disease | Gastrointestinal Diseases | Endocrine System Diseases | Immune System Diseases | Dermatologic disorders | nervous system disorder | Malignant Neoplasms | Musculoskeletal Diseases | Mental disorders | Compliance behavior

Data type

boolean

Alias
UMLS CUI [1]
C0221423
UMLS CUI [2]
C0007222
UMLS CUI [3]
C0023895
UMLS CUI [4]
C0022658
UMLS CUI [5]
C0018939
UMLS CUI [6]
C0017178
UMLS CUI [7]
C0014130
UMLS CUI [8]
C0021053
UMLS CUI [9]
C0037274
UMLS CUI [10]
C0027765
UMLS CUI [11]
C0006826
UMLS CUI [12]
C0026857
UMLS CUI [13]
C0004936
UMLS CUI [14]
C1321605
9. history or clinical evidence of other respiratory disease (e.g., copd, cystic fibrosis)
Description

Other respiratory system diseases | Chronic Obstructive Airway Disease | Cystic Fibrosis

Data type

boolean

Alias
UMLS CUI [1]
C0029582
UMLS CUI [2]
C0024117
UMLS CUI [3]
C0010674
10. recent (within 2 weeks) or current signs or symptoms of a respiratory infection at screening or pre-dose day 1
Description

Respiratory Tract Infections

Data type

boolean

Alias
UMLS CUI [1]
C0035243
11. currently taking theophylline or has taken theophylline in the 3 months prior to screening
Description

Theophylline

Data type

boolean

Alias
UMLS CUI [1]
C0039771
12. use of non-prescription drugs within 3 days prior to day 1
Description

Drugs, Non-Prescription

Data type

boolean

Alias
UMLS CUI [1]
C0013231
13. use of prescription medications (except acceptable asthma medications, acceptable forms of birth control, and hormone replacement) and recreational drugs within 14 days prior to day 1
Description

Prescription Drugs | Pharmaceutical Preparations | Asthma | Contraceptive methods | Hormone replacement therapy | Recreational Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0304227
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0004096
UMLS CUI [3]
C0700589
UMLS CUI [4]
C0282402
UMLS CUI [5]
C0242508
14. positive urine drug screen or breath alcohol test at screening or pre-dose day 1
Description

Urine drug screen positive | Ethanol measurement, breath

Data type

boolean

Alias
UMLS CUI [1]
C0743300
UMLS CUI [2]
C0202306
15. female subjects who are pregnant or lactating or who are planning to become pregnant within 30 days of study drug administration
Description

Pregnancy | Breast Feeding | Pregnancy, Planned

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0032992
16. history of allergy, hypersensitivity, or serious adverse reaction to lactose or neuraminidase inhibitors
Description

Hypersensitivity | Lactose | Neuraminidase

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0022949
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0027803
17. previous exposure to laninamivir octanoate
Description

Exposure to | laninamivir octanoate

Data type

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C3530114
18. positive for hepatitis b surface antigen, hepatitis c virus antibody, or human immunodeficiency virus (hiv) p24 antigen/antibodies at screening
Description

Positive | Hepatitis B Surface Antigens | Hepatitis C Antibodies | HIV Core Protein p24

Data type

boolean

Alias
UMLS CUI [1,1]
C1446409
UMLS CUI [1,2]
C0019168
UMLS CUI [2]
C0166049
UMLS CUI [3]
C0085219
19. donation or loss of ≥500 ml whole blood within 2 months prior to day 1
Description

whole blood | Blood Donation | Hemorrhage

Data type

boolean

Alias
UMLS CUI [1,1]
C0370231
UMLS CUI [1,2]
C0005794
UMLS CUI [2]
C0019080
20. current or pending legal charges or currently on probation, based on subject report
Description

charge amounts | On probation

Data type

boolean

Alias
UMLS CUI [1]
C0007961
UMLS CUI [2]
C0425169
21. receipt of an investigational product in a clinical trial within 30 days or 5 half-lives, whichever is longer, prior to day 1
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
22. concurrent enrolment in any other type of medical research, judged by the investigator not to be scientifically or medically compatible with this study
Description

Study Subject Participation Status | Compliance behavior

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C1321605
23. an employee of the sponsor or research site personnel directly affiliated with this study or their immediate family members defined as a spouse, parent, sibling, or child, whether biological or legally adopted
Description

Employee | Clinical Study Sponsor

Data type

boolean

Alias
UMLS CUI [1,1]
C0599987
UMLS CUI [1,2]
C2347796
24. a subject who, in the opinion of the investigator, is not considered to be suitable and is unlikely to comply with the study protocol for any reason
Description

Compliance behavior

Data type

boolean

Alias
UMLS CUI [1]
C1321605
Back to the top of the page

Similar models

Eligibility Asthma NCT02022761

1 forms
  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT02022761
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age | Gender | Healthy Volunteers
Item
1. healthy male or female subjects 18 to 65 years of age, inclusive
boolean
C0001779 (UMLS CUI [1])
C0079399 (UMLS CUI [2,1])
C1708335 (UMLS CUI [2,2])
Body mass index
Item
2. body mass index (bmi) within the range of 19.0 to 33.0 kg/m2, inclusive at screening
boolean
C1305855 (UMLS CUI [1])
Body weight | Pre-dose | day
Item
3. minimum weight of 55.0 kg at screening and pre-dose day 1
boolean
C0005910 (UMLS CUI [1])
C0439565 (UMLS CUI [2,1])
C0439228 (UMLS CUI [2,2])
Asthma confirmed
Item
4. clinical diagnosis of asthma by a physician for ≥12 months prior to screening confirmed in writing and/or by medical records
boolean
C0004096 (UMLS CUI [1,1])
C3173473 (UMLS CUI [1,2])
Mild asthma | Low-Dose Treatment | inhaled steroids | Moderate asthma | inhaled steroids | Adrenergic beta-2 Receptor Agonists
Item
5. mild asthmatics currently requiring treatment with low dose inhaled corticosteroids or other low intensity treatment or moderate asthmatics, requiring treatment with low dose inhaled corticosteroids and long-acting beta agonists, medium- high dose inhaled corticosteroids alone or low dose inhaled corticosteroids and other low intensity treatment8
boolean
C0581124 (UMLS CUI [1])
C1708745 (UMLS CUI [2,1])
C2065041 (UMLS CUI [2,2])
C0581125 (UMLS CUI [3,1])
C2065041 (UMLS CUI [3,2])
C2936789 (UMLS CUI [3,3])
Persistent asthma, well controlled
Item
6. well controlled asthma for 1 month prior to dosing defined by the following:
boolean
C3661869 (UMLS CUI [1])
Asthma daytime symptoms
Item
1. daytime symptoms occur ≤8 times/ 4 weeks
boolean
C1276804 (UMLS CUI [1])
Asthma | daily activities | Limited
Item
2. daily activity is not limited by asthma
boolean
C0004096 (UMLS CUI [1])
C0871707 (UMLS CUI [2,1])
C0439801 (UMLS CUI [2,2])
Asthma night-time symptoms | Nocturnal awakening
Item
3. no nocturnal symptoms resulting in nighttime awakenings
boolean
C1273489 (UMLS CUI [1])
C0860510 (UMLS CUI [2])
Adrenergic beta-2 Receptor Agonists | treat symptoms
Item
4. use of short-acting beta-agonist (saba) ≤8 times/4 weeks for the treatment of symptoms
boolean
C2936789 (UMLS CUI [1,1])
C2146147 (UMLS CUI [1,2])
Asthma | Change of medication
Item
7. there has been no change in asthma medication (dose or regimen) within 4 weeks prior to dosing
boolean
C0004096 (UMLS CUI [1,1])
C0580105 (UMLS CUI [1,2])
Adrenergic beta-2 Receptor Agonists | FEV1
Item
8. pre-short-acting β2 agonist (saba) forced expiratory volume in 1 second (fev1) of
boolean
C2936789 (UMLS CUI [1])
C0748133 (UMLS CUI [2])
FEV1
Item
≥80 percent of predicted normal values at screening
boolean
C0748133 (UMLS CUI [1])
Non-smoker
Item
9. non-smokers for at least 6 months prior to screening and agrees not to smoke during the study
boolean
C0337672 (UMLS CUI [1])
Smoking Status | Negative Test Result | Urine cotinine test negative
Item
10. negative test results for smoking status at screening (urine cotinine) and pre-dose day 1 (smokerlyser)
boolean
C1519386 (UMLS CUI [1,1])
C1334932 (UMLS CUI [1,2])
C1696067 (UMLS CUI [2])
Childbearing Potential | periodic abstinence | Rhythm method of contraception | Ovulation Inhibition | Temperature method of contraception | Withdrawal - birth control | Contraceptive methods | Hormonal contraception
Item
11. female subjects of childbearing potential must be practising true abstinence when this is in line with the preferred and usual lifestyle of the subject (periodic abstinence, e.g. calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception), or be using and willing to continue using a medically acceptable form of birth control for at least 1 month prior to screening (at least 3 months for hormonal contraceptives) and for at least 1 month after the last study drug administration
boolean
C3831118 (UMLS CUI [1])
C1256761 (UMLS CUI [2])
C0035513 (UMLS CUI [3])
C0029968 (UMLS CUI [4])
C0419534 (UMLS CUI [5])
C3812880 (UMLS CUI [6])
C0700589 (UMLS CUI [7])
C2985296 (UMLS CUI [8])
Male Contraception | Females & males of reproductive potential
Item
12. male subjects of reproductive potential who are not truly abstinent must be using and willing to continue using medically acceptable contraceptive precautions from screening and for at least 1 month after the last study drug administration
boolean
C0086580 (UMLS CUI [1])
C4034483 (UMLS CUI [2])
Female | Serum pregnancy test negative | Urine pregnancy test negative
Item
13. female subjects must have a negative serum pregnancy test at screening and a negative urine pregnancy test pre-dose day 1
boolean
C0086287 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C0430057 (UMLS CUI [1,3])
Able to speak | Able to read | Comprehension | English Language | Informed Consent | Compliance behavior
Item
14. able to speak, read, and understand english sufficiently to understand the nature of the study, to provide informed consent, and to allow completion of all study assessments
boolean
C0564215 (UMLS CUI [1,1])
C0586740 (UMLS CUI [1,2])
C0162340 (UMLS CUI [1,3])
C0376245 (UMLS CUI [1,4])
C0021430 (UMLS CUI [2])
C1321605 (UMLS CUI [3])
Informed consent
Item
15. must provide written informed consent prior to the initiation of any protocol-specific procedures
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Exacerbation of asthma | Life Threatening | Intubation | Mechanical ventilation
Item
1. a history of a life-threatening asthma exacerbation that required intubation and mechanical ventilation
boolean
C0349790 (UMLS CUI [1,1])
C2826244 (UMLS CUI [1,2])
C0021925 (UMLS CUI [2,1])
C0199470 (UMLS CUI [2,2])
Exacerbation of severe persistent asthma | systemic steroids
Item
2. history of severe asthma exacerbation in the last year that required the use of systemic corticosteroids (tablets, suspension or injection)
boolean
C3508930 (UMLS CUI [1])
C2825233 (UMLS CUI [2])
Hospitalization | previous emergency room visit | Asthma
Item
3. hospitalization or a visit to er because of asthma in the last year
boolean
C0019993 (UMLS CUI [1])
C2114437 (UMLS CUI [2])
C0004096 (UMLS CUI [3])
Asthma | Admission to intensive care unit
Item
4. intensive care admission for asthma in the previous 5 years
boolean
C0004096 (UMLS CUI [1,1])
C0583239 (UMLS CUI [1,2])
Abnormality | Chemistry, Clinical | Hematology finding | Urinalysis
Item
5. any clinically significant abnormalities on clinical chemistry, haematology, or urinalysis, as judged by the investigator (at screening and/or day -1)
boolean
C1704258 (UMLS CUI [1,1])
C0008000 (UMLS CUI [1,2])
C0474523 (UMLS CUI [2])
C0042014 (UMLS CUI [3])
Abnormality | Physical Examination | Medical History | 12 lead ECG | Vital signs
Item
6. clinically significant abnormalities on physical examination, medical history, 12-lead ecg, or vital signs, as judged by the investigator (at screening or pre-dose day 1)
boolean
C1704258 (UMLS CUI [1,1])
C0031809 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2])
C0430456 (UMLS CUI [3])
C0518766 (UMLS CUI [4])
QTcF | Gender | Electrocardiogram
Item
7. a qtcf >430 msec for male subjects and >450 msec for female subjects on ecg at screening or pre-dose day 1
boolean
C1882513 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
C0013798 (UMLS CUI [3])
Illness (finding) | Cardiovascular Diseases | Liver diseases | Kidney Diseases | Hematological Disease | Gastrointestinal Diseases | Endocrine System Diseases | Immune System Diseases | Dermatologic disorders | nervous system disorder | Malignant Neoplasms | Musculoskeletal Diseases | Mental disorders | Compliance behavior
Item
8. history or presence of any clinically significant illness (e.g., cardiovascular, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, musculoskeletal, or psychiatric) or any other condition, which in the opinion of the investigator would jeopardize the safety of the subject or the validity of the study results
boolean
C0221423 (UMLS CUI [1])
C0007222 (UMLS CUI [2])
C0023895 (UMLS CUI [3])
C0022658 (UMLS CUI [4])
C0018939 (UMLS CUI [5])
C0017178 (UMLS CUI [6])
C0014130 (UMLS CUI [7])
C0021053 (UMLS CUI [8])
C0037274 (UMLS CUI [9])
C0027765 (UMLS CUI [10])
C0006826 (UMLS CUI [11])
C0026857 (UMLS CUI [12])
C0004936 (UMLS CUI [13])
C1321605 (UMLS CUI [14])
Other respiratory system diseases | Chronic Obstructive Airway Disease | Cystic Fibrosis
Item
9. history or clinical evidence of other respiratory disease (e.g., copd, cystic fibrosis)
boolean
C0029582 (UMLS CUI [1])
C0024117 (UMLS CUI [2])
C0010674 (UMLS CUI [3])
Respiratory Tract Infections
Item
10. recent (within 2 weeks) or current signs or symptoms of a respiratory infection at screening or pre-dose day 1
boolean
C0035243 (UMLS CUI [1])
Theophylline
Item
11. currently taking theophylline or has taken theophylline in the 3 months prior to screening
boolean
C0039771 (UMLS CUI [1])
Drugs, Non-Prescription
Item
12. use of non-prescription drugs within 3 days prior to day 1
boolean
C0013231 (UMLS CUI [1])
Prescription Drugs | Pharmaceutical Preparations | Asthma | Contraceptive methods | Hormone replacement therapy | Recreational Drugs
Item
13. use of prescription medications (except acceptable asthma medications, acceptable forms of birth control, and hormone replacement) and recreational drugs within 14 days prior to day 1
boolean
C0304227 (UMLS CUI [1])
C0013227 (UMLS CUI [2,1])
C0004096 (UMLS CUI [2,2])
C0700589 (UMLS CUI [3])
C0282402 (UMLS CUI [4])
C0242508 (UMLS CUI [5])
Urine drug screen positive | Ethanol measurement, breath
Item
14. positive urine drug screen or breath alcohol test at screening or pre-dose day 1
boolean
C0743300 (UMLS CUI [1])
C0202306 (UMLS CUI [2])
Pregnancy | Breast Feeding | Pregnancy, Planned
Item
15. female subjects who are pregnant or lactating or who are planning to become pregnant within 30 days of study drug administration
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032992 (UMLS CUI [3])
Hypersensitivity | Lactose | Neuraminidase
Item
16. history of allergy, hypersensitivity, or serious adverse reaction to lactose or neuraminidase inhibitors
boolean
C0020517 (UMLS CUI [1,1])
C0022949 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0027803 (UMLS CUI [2,2])
Exposure to | laninamivir octanoate
Item
17. previous exposure to laninamivir octanoate
boolean
C0332157 (UMLS CUI [1,1])
C3530114 (UMLS CUI [1,2])
Positive | Hepatitis B Surface Antigens | Hepatitis C Antibodies | HIV Core Protein p24
Item
18. positive for hepatitis b surface antigen, hepatitis c virus antibody, or human immunodeficiency virus (hiv) p24 antigen/antibodies at screening
boolean
C1446409 (UMLS CUI [1,1])
C0019168 (UMLS CUI [1,2])
C0166049 (UMLS CUI [2])
C0085219 (UMLS CUI [3])
whole blood | Blood Donation | Hemorrhage
Item
19. donation or loss of ≥500 ml whole blood within 2 months prior to day 1
boolean
C0370231 (UMLS CUI [1,1])
C0005794 (UMLS CUI [1,2])
C0019080 (UMLS CUI [2])
charge amounts | On probation
Item
20. current or pending legal charges or currently on probation, based on subject report
boolean
C0007961 (UMLS CUI [1])
C0425169 (UMLS CUI [2])
Investigational New Drugs
Item
21. receipt of an investigational product in a clinical trial within 30 days or 5 half-lives, whichever is longer, prior to day 1
boolean
C0013230 (UMLS CUI [1])
Study Subject Participation Status | Compliance behavior
Item
22. concurrent enrolment in any other type of medical research, judged by the investigator not to be scientifically or medically compatible with this study
boolean
C2348568 (UMLS CUI [1])
C1321605 (UMLS CUI [2])
Employee | Clinical Study Sponsor
Item
23. an employee of the sponsor or research site personnel directly affiliated with this study or their immediate family members defined as a spouse, parent, sibling, or child, whether biological or legally adopted
boolean
C0599987 (UMLS CUI [1,1])
C2347796 (UMLS CUI [1,2])
Compliance behavior
Item
24. a subject who, in the opinion of the investigator, is not considered to be suitable and is unlikely to comply with the study protocol for any reason
boolean
C1321605 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial